BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dositinib mesylate readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Dositinib mesylate\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07362940-2458@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Dositinib mesylate: Phase 1/2 readout est. (NCT07362940)
DESCRIPTION:Dositinib mesylate\, phase 1/2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dosit
 inib\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/dositinib-mesylate#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07362940
URL:https://assetmemo.bio/drug/dositinib-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07231068-2458@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dositinib mesylate: Phase 1/2 readout est. (NCT07231068)
DESCRIPTION:Dositinib mesylate\, phase 1/2\, Non-Small Cell Lung Cancer.\nS
 tudy: A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study
  of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advan
 ced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dositinib-mesylate#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07231068
URL:https://assetmemo.bio/drug/dositinib-mesylate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
